![]() |
½ÃÀ庸°í¼
»óǰÄÚµå
1527285
¼¼°èÀÇ ¾Æ½ºÇǸ° ¾à¹° ½ÃÀå ±Ô¸ð Á¶»ç : Á¦Ç° À¯Çüº°, Åõ¿©Çüº°, Åõ¿© °æ·Îº°, ¿¬·Éº°, À¯Åë ä³Îº°, Áö¿ªº° ¿¹Ãø(2022-2032³â)Global Aspirin Drug Market Size study, by Product Type, by Dosage Form, by Route of Administration, by Age, by Distribution Channel and Regional Forecasts 2022-2032 |
¼¼°èÀÇ ¾Æ½ºÇǸ° ¾à¹° ½ÃÀåÀº 2023³â¿¡ ¾à 28¾ï 3,064¸¸ ´Þ·¯·Î Æò°¡µÇ¾ú°í, ¿¹Ãø ±â°£ 2024³âºÎÅÍ 2032³â±îÁö 3.8% ÀÌ»óÀÇ °ß½ÇÇÑ ¼ºÀå·ü·Î ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹ÃøµÇ°í ÀÖ½À´Ï´Ù.
°úÇÐÀûÀ¸·Î ¾Æ¼¼Æ¿»ì¸®½Ç»êÀ¸·Î ¾Ë·ÁÁø ¾Æ½ºÇǸ° ¾à¹°Àº ÁøÅë, Ç׿°Áõ, ÇØ¿ ÀÛ¿ëÀÌ ÀÖÀ¸¸ç ÀϹÝÀûÀÎ ÀǾàǰÀ¸·Î »ç¿ëµÇ°í ÀÖ½À´Ï´Ù. »çÀÌŬ·Î¿Á½Ã°Ô³ªÁ¦(COX) È¿¼Ò¸¦ ¾ïÁ¦ÇÔÀ¸·Î½á ¿°Áõ, ÅëÁõ, ¹ß¿À» ¸Å°³ÇÏ´Â ÇÁ·Î½ºÅ¸±Û¶õµòÀÇ »ý»êÀ» ¾ïÁ¦ÇÕ´Ï´Ù. °æÁõ¿¡¼ ÁߵÀÇ ÅëÁõÀ» ¿ÏȽÃ۰í, ¿À» ³·Ãß°í, °üÀý¿°°ú °°Àº ¿°Áõ¼º »óÅÂ¿Í °ü·ÃµÈ Áõ»óÀ» Ä¡·áÇϱâ À§ÇØ ³Î¸® Åõ¿©µÇ¾úÁö¸¸, ¾Æ½ºÇǸ° ¾à¹°Àº Àú¿ë·®À¸·Î Ç÷ÀüÀ» ¿¹¹æÇϴµ¥µµ »ç¿ëµÇ¸ç, ±× °á°ú, ½ÉÇ÷°ü ÁúȯÀ» °¡Áø »ç¶÷ÀÇ ½ÉÀå ¸¶ºñ¿Í ³úÁ¹ÁßÀÇ À§ÇèÀ» ÃÖ¼ÒÈÇÕ´Ï´Ù. ±× Ç÷¾×À» ¸¼°Ô Çϴ Ư¼ºÀ¸·ÎºÎÅÍ, ½ÉÀ庴À̳ª ³úÁ¹ÁßÀÇ ±â¿Õ·ÂÀÌ Àִ ȯÀÚ¿¡°Ô Àå±âÀûÀ¸·Î »ç¿ëµÇ´Â ÀϹÝÀûÀΠ󹿾àÀÌ µÇ°í ÀÖ½À´Ï´Ù.
¾Æ½ºÇǸ° ¾à¹° ½ÃÀå ¼ºÀåÀº ÁÖ·Î °üÀý¿°, ÅëÁõ, ¿°Áõ°ú °°Àº Áúº´ÀÇ À¯º´·üÀÌ Áõ°¡ÇÏ¿© ¹ß»ýÇÕ´Ï´Ù. Àα¸ »çÀÌ¿¡¼ ½ÅÀå Àå¾Ö, ½ÉÇ÷°ü Áúȯ, ³úÁ¹Áß µî ¸¸¼º ÁúȯÀÇ ¹ß»ý·üÀÌ »ó½ÂÇϰí ÀÖ´Â °ÍÀÌ ¾Æ½ºÇǸ° ¾à¹° ½ÃÀåÀ» Å©°Ô ÀüÁø½Ã۰í ÀÖ½À´Ï´Ù. ½É±Ù°æ»ö¿¡ ´ëÇÑ ÀνÄÀ» ³ÐÈ÷´Â °ÍÀ» ¸ñÀûÀ¸·Î ÇÏ´Â °ø°ø±â°üÀ̳ª ¹Î°£´Üü¿¡ ÀÇÇÑ ´ëó°¡ ½ÃÀå ±Ô¸ð¸¦ ´õ¿í È®´ëÇϰí ÀÖ½À´Ï´Ù. °³¹ß µµ»ó±¹°ú ¼±Áø±¹ ¸ðµÎ¿¡¼ °í ÄÝ·¹½ºÅ×·Ñ ½ÄǰÀÇ ¼·Ãë, Èí¿¬ ¹× ±âŸ ¿äÀÎÀ» Æ÷ÇÔÇÑ ¶óÀÌÇÁ ½ºÅ¸ÀÏ º¯È·Î ÀÎÇÑ ½ÉÇ÷°ü ÁúȯÀÇ À¯º´·ü Áõ°¡´Â ¾Æ½ºÇǸ° ¾à¹° Á¦Á¶¾÷ü¿¡°Ô Å« ºñÁî´Ï½º ±âȸ¸¦ Á¦°øÇÕ´Ï´Ù. Ç÷Àü, ½ÉÀå ¹ßÀÛ ¹× ½ÉÀå Á¶Á÷ ÆÄ±«¿Í °ü·ÃµÈ »ç°ÇÀÇ ±ÞÁõÀº ÀÇ·á Àü¹®°¡¿¡°Ô ÀÌ·¯ÇÑ Áõ»óÀÇ Ä¡·á¿¡ È¿°úÀûÀÎ ¾Æ½ºÇǸ° ¾à¹° ó¹æÀ» Ã˱¸ÇÕ´Ï´Ù.
¶ÇÇÑ ÀǾàǰ À¯È¿¼ººÐ(API)ÀÇ ¹üÀ§°¡ È®´ëµÇ¾î ÀǾàǰ Á¦Á¦·ÎÀÇ ÀÌ¿ëÀÌ ÇöÀúÇÑ ½ÃÀå ¼ºÀå ÃËÁø¿äÀÎÀÌ µÇ°í ÀÖ½À´Ï´Ù. COX ÀÇÁ¸¼º ¹× ºñÀÇÁ¸¼º ¸ÞÄ¿´ÏÁò¿¡¼ ¾Æ½ºÇǸ° ¾à¹°ÀÇ È¿´ÉÀº ´ç´¢º´, ¾Ï, ½Å°æ°è Àå¾Ö, Å©¸³ÅäÄÚÄ¿½º °¨¿°À» Æ÷ÇÔÇÑ ¿©·¯ Áúº´ÀÇ ¿¹¹æ¿¡ Áß¿äÇÑ ¿ªÇÒÀ» ÇÕ´Ï´Ù. Ç÷Àü°ú °ü·ÃµÈ ³ôÀº ÀÌȯ À§ÇèÀº Ç×Ç÷¾× ÀÀ°í Ư¼ºÀ¸·Î ¾Æ½ºÇǸ° ¾à¹°ÀÇ »ç¿ë·®À» Áõ°¡½Ã۰í ȯÀÚ°¡ ´ëü Ä¡·á¸¦ ¹Þ´Â µ¿¾È ºÎµå·¯¿î Ç÷·ù¸¦ º¸ÀåÇÕ´Ï´Ù. ÀÌ·¯ÇÑ ¾Æ½ºÇǸ° ¾à¹°ÀÇ °í±Þ ¿ëµµ´Â ½ÃÀå ¼ö¿ä¸¦ À¯ÁöÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.
Áö¿ªÀûÀ¸·Î ºÏ¹Ì´Â ¼¼°èÀÇ ¾Æ½ºÇǸ° ¾à¹° ½ÃÀåÀ» µ¶Á¡ÇÏ°í ¿¹Ãø ±â°£ µ¿¾È °¡Àå Å« ½ÃÀå Á¡À¯À²À» À¯ÁöÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ¹Ì±¹¿¡¼´Â Bayer AG, Dr. Reddy's Laboratories, Sanofi SA µîÀÇ À¯¸í ºê·£µå°¡ ½ÃÀåÀ» µ¶Á¡Çϰí ÀüÅëÀûÀÎ Á¦Çü¿¡¼ Çõ½ÅÀûÀÎ Ä¡·á ¼Ö·ç¼Ç¿¡ À̸£±â±îÁö ±¤¹üÀ§ÇÑ ¾Æ½ºÇǸ° ¾à¹° Á¦Ç°À» Á¦°øÇÕ´Ï´Ù. ÀÌ Áö¿ª ½ÃÀåÀº ±âÁ¸ÀÇ ¼Ò¸ÅÁ¡°ú ±Þ¼ºÀåÇÏ´Â ¿Â¶óÀÎ ÆÇ¸Å Ç÷§ÆûÀÌ È¥ÀçÇϰí ÀÖ´Â °ÍÀÌ Æ¯Â¡À¸·Î, ÀüÀÚ»ó°Å·¡°¡ Å« °ßÀηÂÀÌ µÇ°í ÀÖ½À´Ï´Ù. ¹Ì±¹ ¼ÒºñÀÚ´Â ±â´É¼º°ú ÆíÀǼºÀ» ¸ðµÎ ¼±È£ÇÏ°í ½Å·Ú¼º°ú È¿´ÉÀ» °®Ãá ¾Æ½ºÇǸ° ¾à¹° Á¦Ç°À» ¼±ÅÃÇÕ´Ï´Ù. ¹Ý¸é ¾Æ½Ã¾ÆÅÂÆò¾ç ½ÃÀåÀº 2024³âºÎÅÍ 2032³â±îÁö ¿¹Ãø±â°£¿¡¼ °¡Àå ºü¸¥ ¼Óµµ·Î ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.
The global aspirin drug market is valued at approximately USD 2,830.64 million in 2023 and is anticipated to grow with a healthy growth rate of more than 3.8% over the forecast period 2024-2032. Aspirin, scientifically known as acetylsalicylic acid, serves as a prevalent medication attributed to its analgesic, anti-inflammatory, and antipyretic properties. It functions by inhibiting the cyclooxygenase (COX) enzymes, thereby reducing the production of prostaglandins responsible for mediating inflammation, pain, and fever. Widely administered for alleviating mild to moderate pain, reducing fever, and treating symptoms associated with inflammatory conditions such as arthritis, aspirin is also employed in low doses to prevent blood clots, consequently minimizing the risk of heart attacks and strokes in individuals with cardiovascular conditions. Its blood-thinning characteristics make it a common prescription for long-term use in patients with a history of heart diseases or strokes.
The market growth for aspirin is primarily driven by the increasing prevalence of conditions such as arthritis, pain, and inflammation. The rising incidence of chronic ailments like renal disorders, cardiovascular diseases, and brain strokes among populations is significantly propelling the aspirin drug market forward. Initiatives by public and private organizations aimed at spreading awareness regarding myocardial infarction further amplify the market scope. The escalating prevalence of cardiovascular diseases, attributed to lifestyle changes involving high-cholesterol food consumption, smoking, and other factors, in both developing and developed nations, presents substantial business opportunities for aspirin manufacturers. The surge in incidents related to clots, heart attacks, and heart tissue destruction is prompting medical professionals to prescribe aspirin for its efficacy in treating these conditions.
Moreover, the expanding scope of active pharmaceutical ingredients (APIs) and their utilization in drug formulation is a noteworthy market driver. Aspirin's effectiveness in COX-dependent and independent mechanisms plays a crucial role in preventing several diseases, including diabetes, cancer, nervous system disorders, and cryptococcal infections. The high morbidity risk associated with blood clots fosters the increased usage of aspirin due to its anti-clotting properties, ensuring smooth blood flow while patients receive alternative medical treatments. This advanced application of aspirin is predicted to sustain market demand.
Regionally, North America is expected to dominate the Global Aspirin Drug Market, holding the largest market share during the forecast period. Prominent brands such as Bayer AG, Dr. Reddy's Laboratories, and Sanofi S.A dominate the market in the U.S., offering a wide range of aspirin products, from traditional formulations to innovative therapeutic solutions. The region's market is characterized by a robust mix of traditional retail outlets and burgeoning online sales platforms, with e-commerce gaining significant traction. Consumers in the U.S. prioritize both functionality and convenience, opting for aspirin products that offer reliability and efficacy. Whereas, the market in Asia Pacific is anticipated to grow at the fastest rate over the forecast period 2024-2032